flow trial semaglutide all-cause mortality hazard ratio Long-term kidney outcomes of in obesity and cardiovascular disease in the SELECT Semaglutide flow trial semaglutide kidney outcomes

Slow digestion-oriented dietary strategy to sustain the secretion of GLP-1 for improved glucose homeostasis

This can cause visible bloating if not managed properly, which would be problematic in the final days before stage

The benefits of treating obesity often outweigh age-related concerns

From the research were seeing people experience nutrient deficiencies, muscle loss, and reduced bone density because these medications reduce calories from food by around 19-39%

When to seek medical review should be clearly communicated

It can also reduce appetite and increase feelings of fullness after eating, which may promote weight loss for some